Over the last six months, Organon’s shares have sunk to $9.03, producing a disappointing 5.9% loss - a stark contrast to the S&P 500’s 2.5% gain. This may have investors wondering how to approach the situation.
Is there a buying opportunity in Organon, or does it present a risk to your portfolio? Get the full breakdown from our expert analysts, it’s free.
Why Is Organon Not Exciting?
Even with the cheaper entry price, we don't have much confidence in Organon. Here are three reasons why OGN doesn't excite us and a stock we'd rather own.
1. Long-Term Revenue Growth Flatter Than a Pancake
A company’s long-term performance is an indicator of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Unfortunately, Organon struggled to consistently increase demand as its $6.22 billion of sales for the trailing 12 months was close to its revenue five years ago. This wasn’t a great result and is a sign of lacking business quality.
2. EPS Trending Down
We track the long-term change in earnings per share (EPS) because it highlights whether a company’s growth is profitable.
Organon’s full-year EPS dropped 61.7%, or 12.8% annually, over the last four years. We tend to steer our readers away from companies with falling revenue and EPS, where diminishing earnings could imply changing secular trends and preferences. If the tide turns unexpectedly, Organon’s low margin of safety could leave its stock price susceptible to large downswings.
3. Free Cash Flow Margin Dropping
Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king.
As you can see below, Organon’s margin dropped by 22.6 percentage points over the last five years. If its declines continue, it could signal increasing investment needs and capital intensity. Organon’s free cash flow margin for the trailing 12 months was 8.7%.
Final Judgment
Organon isn’t a terrible business, but it doesn’t pass our bar. After the recent drawdown, the stock trades at 2× forward P/E (or $9.03 per share). While this valuation is optically cheap, the potential downside is big given its shaky fundamentals. We're pretty confident there are superior stocks to buy right now. We’d recommend looking at the Amazon and PayPal of Latin America.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
